MEMO THERAPEUTICS
Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis. Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’s immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery. MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.
MEMO THERAPEUTICS
Industry:
Biotechnology Collaboration
Founded:
2012-01-01
Address:
Schlieren, Zurich, Switzerland
Country:
Switzerland
Website Url:
http://www.memo-therapeutics.com
Total Employee:
1+
Status:
Active
Contact:
+41 44 515 91 40
Total Funding:
59.15 M USD
Technology used in webpage:
IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon Content Delivery Network Microsoft Exchange Online Office 365 Mail ReCAPTCHA
Similar Organizations
Adrestia Therapeutics
Adrestia is developing therapeutics that work in an entirely new way – restoring the biological balance in damaged, diseased or dying cells
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Amsterdam Scientific Instruments
Amsterdam Scientific Instruments specializes in the fields of neutron detection, electron imaging, and X-ray detector technology.
Anocca AB
Anocca AB provides services like Biotechnology, Immunotherapeutics, Drug Discovery, Drug Development, Immunology.
Aphea.Bio
Aphea.Bio offers research and development in the areas of bioinsecticides and bioherbicides.
BIOT
BIOT is dedicated to research and innovation in the field of microbiology and biotechnology.
Bluu Seafood
Bluu Seafood Provides Sea Food Manufacturing Services.
Celtic Renewables
Celtic Renewables is a biofuel startup focused on the renewable energy and whisky sector.
Domainex
A fully integrated drug discovery service company.
EMMAC Life Sciences
EMMAC is a medical cannabis company that works to join together the latest science and research with cutting-edge cultivation.
ETHRIS
ETHRIS is a technical innovator in the emerging field of mRNA therapeutics and LNP delivery.
Evariste Technologies
Biotech using quantitative modelling to make drug discovery more efficient
genomes.io
genomes.io is a human genome is the blueprint to what makes you who you are.
Hoxton Farms
Based in London, UK, Hoxton Farms is growing cultivated fat as an ingredient for the meat alternatives industry.
IMVAQ Therapeutics
Imvaq Therapeutics is an innovative cancer immunotherapy company.
Infinited Fiber Company
Infinited Fiber Company is on a mission to make circular fashion and textiles an everyday reality
KYMIRA Sport
KYMIRA Sport is developing a range of performance and recovery enhancing sportswear.
Leucid Bio
Leucid is progressing novel cart therapies that produce a better and more durable response.
Mnemo Therapeutics
Mnemo Therapeutics specializes in biotechnology and life science.
ORF Genetics
ORF Genetics is an innovative company that is committed to economically viable and enabling solutions.
Pandion Therapeutics
Pandion Therapeutics develops innovative modular proteins, antibodies, and bispecifics for autoimmune and inflammatory diseases.
PATS
PATS is an Indoor Drone Solutions enables greenhouse farmers to significantly reduce and eliminate flying insect pest populations
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
STipe Therapeutics
STipe Therapeutics focuses on harnessing the innate immune system to battle cancer.
Telomere Therapeutics
Telomere Therapeutics is a University of Barcelona spinoff developing telomerase gene therapy to treat pulmonary fibrosis
Current Advisors List
Board_member
2015-01-01
Board_member
2022-02-16
Board_member
2022-02-16
Board_member
2022-02-16
Current Employees Featured
Christoph Esslinger Founder & CEO @ Memo Therapeutics
Founder & CEO
Founder
Investors List
Verve Ventures
Verve Ventures investment in Series B - Memo Therapeutics
Fresenius Medical Care
Fresenius Medical Care investment in Series B - Memo Therapeutics
Zürcher Kantonal Bank
Zürcher Kantonal Bank investment in Series B - Memo Therapeutics
Vesalius Biocapital Partners
Vesalius Biocapital Partners investment in Series B - Memo Therapeutics
Adjuvant Capital
Adjuvant Capital investment in Series B - Memo Therapeutics
GF Group Holding
GF Group Holding investment in Series B - Memo Therapeutics
Swisscanto Private Equity
Swisscanto Private Equity investment in Series B - Memo Therapeutics
Federal Office of Public Health (FOPH) Switzerland
Federal Office of Public Health (FOPH) Switzerland investment in Grant - Memo Therapeutics
Bernina BioInvest
Bernina BioInvest investment in Series B - Memo Therapeutics
Redalpine
Redalpine investment in Series B - Memo Therapeutics
Official Site Inspections
http://www.memo-therapeutics.com
- Host name: 185-151-30-220.ptr4.stackcp.net
- IP address: 185.151.30.220
- Location: United Kingdom
- Latitude: 51.4964
- Longitude: -0.1224
- Timezone: Europe/London
More informations about "Memo Therapeutics"
Memo Therapeutics AG | Best-in-Class Therapeutic Antibodies
Memo Therapeutics AG is a late-stage biotech company developing best-in-class therapeutic antibodies to transform the lives of patients with viral infections and cancer. Our lead program, …See details»
About Us - Memo Therapeutics AG
Memo Therapeutics AG is a late-stage biotech company developing best-in-class therapeutic antibodies to transform the lives of patients with viral infections and cancer. Our mission is to improve the standard of care for patients with viral …See details»
Memo Therapeutics - Crunchbase Company Profile
Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis. Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then …See details»
Memo Therapeutics AG - Swiss Biotech
Memo Therapeutics AG (“MTx”) is a late-stage biotech company translating unique human immune responses into superior medicines through the development of best-in-class …See details»
Memo Therapeutics AG - LinkedIn
Memo Therapeutics AG (“MTx”) is a late-stage biotech company translating unique human immune responses into superior medicines through the development of best-in-class antibodies to treat viral...See details»
Memo Therapeutics AG Appoints Paul Carter as Chairperson
Jul 8, 2024 · Schlieren / Zurich, Switzerland, 8 July, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to …See details»
Memo Therapeutics AG Appoints Erik van den Berg as …
Nov 16, 2023 · ZURICH-- ( BUSINESS WIRE )-- Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the appointment of Erik van den Berg as...See details»
Memo Therapeutics - VentureRadar
Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis. Exploiting the power of our microfluidic single-cell molecular cloning and screening …See details»
Memo Therapeutics AG Raises CHF 25 Million Series C …
Nov 2, 2023 · Memo Therapeutics AG (“MTx”) is a late-stage biotech company developing best-in-class therapeutic antibodies to transform the lives of patients with virus infections and cancer.See details»
Memo Therapeutics AG Receives FDA Fast Track ... - Business Wire
May 2, 2023 · Memo Therapeutics AG (“MTx”) is a late-stage biotech company developing best-in-class therapeutic antibodies to transform the lives of patients with virus infections and …See details»
Memo Therapeutics - Contacts, Employees, Board Members
Memo Therapeutics is an innovator in the field of antibody discovery and immune repertoire analysis.See details»
Interview Erik van den Berg - verve.vc
Mar 19, 2024 · Industry veteran Erik van den Berg joined Verve Ventures’ portfolio company Memo Therapeutics right after it raised CHF 25 million in late 2023. The company is now at a …See details»
Latest news - Memo Therapeutics
Stay up-to-date and get all the latest news and information and company news at Memo Therapeutics AG. Find out more.See details»
Ono Enters a Drug Discovery Collaboration Agreement with Memo ...
Nov 1, 2022 · Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis. The company’s antibody discovery platform uses robust, simple, …See details»
Memo Therapeutics AG Closes Series B Financing at CHF37 Million ...
Feb 16, 2022 · Memo Therapeutics AG is a private company located in Bio-Technopark Zurich, Switzerland. Memo Therapeutics AG has closed oversubscribed Series B financing led by …See details»
Memo Therapeutics AG Appoints Frits van Alphen, MD as Chief …
Nov 4, 2024 · Schlieren / Zurich, Switzerland, 4 November, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company translating unique immune responses into superior …See details»
Memo Therapeutics raises $27.7 million to develop antibody …
Nov 2, 2023 · The Swiss biotech company Memo Therapeutics (MTx) has bagged CHF 25 million ($27.7 million) in a Series C round to finish the phase 2 development of its lead antibody …See details»
Memo Therapeutics AG to clinically develop SARS-CoV-2 antibody
Dec 13, 2021 · Memo Therapeutics AG will receive CHF 10.5m (US $11.4m) from the Swiss government to clinically develop a SARS-CoV-2 antibody against COVID-19, allowing it to …See details»
Memo Therapeutics AG and Ono - Business Wire
Nov 1, 2022 · SCHLIEREN, Switzerland & OSAKA, Japan-- ( BUSINESS WIRE )-- Memo Therapeutics AG (“MTx”), an innovator in the field of antibody discovery and development, …See details»
Oncology | Memo Therapeutics AG
Our aim is to discover the antibodies that can be generated against tumors, and utilise them to develop better medicines. Find out more about oncology.See details»